Novo Nordisk's Phase 3 topline release prompted a sharp pre-market sell-off, signalling investor disappointment about Cagrisema's results.
Investors sold Novo Nordisk after the company published topline Phase 3 results for once-weekly Cagrisema. The quick 4.8% pre-market drop and the phrase 'fell sharply' show market disappointment about those results, which lowers confidence in the drug's near prospects. A prior EMA committee support for a different Novo drug is positive, but it does not change the immediate reaction to the Cagrisema data.
Telix signed a strategic agreement to lead a merger, which is positive, but its shares fell 7.9% pre-market, leaving mixed signals.
Aligos shares fell sharply in pre-market trading, indicating negative investor reaction today without offsetting news.
Li Auto shares dipped 3.5% in pre-market trading, while the company recently launched its Li i9 SUV, producing mixed signals.
New Pacific Metals shares declined in pre-market trading, showing immediate downward pressure with no positive offset in the report.
Inventiva ADRs dropped in pre-market trading, reflecting negative sentiment for the stock in this session.
Follow Novo Nordisk A/S (NVO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVO